Excelsior Biopharma (Taiwan) Today
| 6496 Stock | TWD 29.50 0.45 1.55% |
PerformanceVery Weak
| Odds Of DistressAverage
|
Excelsior Biopharma is selling for under 29.50 as of the 14th of March 2025; that is 1.55% up since the beginning of the trading day. The stock's lowest day price was 28.85. Excelsior Biopharma has 51 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 14th of December 2024 and ending today, the 14th of March 2025. Click here to learn more.
Moving together with Excelsior Stock
Moving against Excelsior Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Excelsior Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Excelsior Biopharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Excelsior Biopharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Drug Manufacturers-Specialty & Generic, Healthcare (View all Sectors) |
Excelsior Biopharma (6496) is traded on Taiwan OTC Exchange in Taiwan and employs 23 people. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.32 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Excelsior Biopharma's market, we take the total number of its shares issued and multiply it by Excelsior Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Excelsior Biopharma operates under Healthcare sector and is part of Drug Manufacturers-Specialty & Generic industry. The entity has 46.69 M outstanding shares.
Excelsior Biopharma generates positive cash flow from operations, but has no cash available
Check Excelsior Biopharma Probability Of Bankruptcy
Ownership AllocationExcelsior Biopharma holds a total of 46.69 Million outstanding shares. Excelsior Biopharma shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 61.0 percent of Excelsior Biopharma outstanding shares that are owned by insiders denotes they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Excelsior Ownership Details
Excelsior Biopharma Risk Profiles
Although Excelsior Biopharma's alpha and beta are two of the key measurements used to evaluate Excelsior Biopharma's performance over the market, the standard measures of volatility play an important role as well.
Excelsior Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Excelsior Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Bonds Directory Now
Bonds DirectoryFind actively traded corporate debentures issued by US companies |
| All Next | Launch Module |
Excelsior Biopharma Corporate Management
Elected by the shareholders, the Excelsior Biopharma's board of directors comprises two types of representatives: Excelsior Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Excelsior. The board's role is to monitor Excelsior Biopharma's management team and ensure that shareholders' interests are well served. Excelsior Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Excelsior Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| HuiChen Liu | Representative Mang | Profile | |
| Joseph Chen | Chairman, Founder | Profile | |
| MingTse Chen | Financial Accountant | Profile | |
| PoTang Cheng | Sales Director | Profile | |
| Chialing Chen | New Director | Profile |
Additional Tools for Excelsior Stock Analysis
When running Excelsior Biopharma's price analysis, check to measure Excelsior Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Excelsior Biopharma is operating at the current time. Most of Excelsior Biopharma's value examination focuses on studying past and present price action to predict the probability of Excelsior Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Excelsior Biopharma's price. Additionally, you may evaluate how the addition of Excelsior Biopharma to your portfolios can decrease your overall portfolio volatility.